Use Profiling Data to Reduce PROTACs and RIPTACs Program Delays
About this webinar
Early discovery programs for PROTACs and RIPTACs often face pressure to move quickly while generating the chemistry and biology data needed to support compound selection and program progression. This webinar demonstrates how chemical synthesis and in vitro profiling can be combined to rapidly generate, optimize and advance these molecules in early discovery programs.
The featured speakers will cover strategies for efficiently synthesizing PROTACs and RIPTACs, separating isomers and tuning linkers, warheads and E3 ligase ligands. A case study of a recently synthesized RIPTAC will be discussed to illustrate how rapid synthesis and careful characterization enabled its use in both in vitro and in vivo testing. Practical considerations for the synthesis of molecular glues will also be highlighted.
The session will also focus on in vitro profiling, including degrader assays for PROTACs and proximity-based assays for RIPTACs. Attendees will see how assay data can guide compound prioritization and inform early discovery decisions.
Register for this webinar to learn how integrated synthesis and in vitro profiling can reduce early discovery delays in PROTACs and RIPTACs.
Who should attend
- Medicinal and synthetic chemists
- Chemical, discovery and translational biologists
- Scientists working on PROTACs, RIPTACs, molecular glues or induced proximity
- DMPK, ADME and pharmacology scientists involved in compound profiling
- Project leaders, program directors and decision-makers evaluating strategies or external partners for early discovery
What you will learn
- Strategies for efficiently synthesizing and optimizing PROTACs and RIPTACs, including isomer separation and tuning linkers, warheads, and E3 ligase ligands
- Key lessons from real-world discovery projects to overcome common synthesis challenges
- How in vitro assays are used to characterize compounds and support optimization
- How biological insights enable effective screening prioritization and faster decision-making
- Case studies showing how chemistry and biology combine to accelerate RIPTACs and PROTACs discovery
Featured Speakers
Yanchun Guo, PhD
Dr. Yanchun Guo received her PhD degree from Ulm University in Germany and completed her postdoctoral training at the City of Hope National Medical Center in the US. With extensive experience in gene editing and cancer biology, Dr. Yanchun Guo joined BioDuro in 2019 and established an in vitro evaluation platform for both PROTAC and RIPTAC drug discovery from scratch. These platforms, led by Dr. Guo, have received widespread recognition from many clients.
Xingao Peng, PhD
Dr. Xingao Peng received his PhD degree from the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences in 2008, and then completed postdoctoral training at Colorado State University in the US and Nanyang Technological University in Singapore. With extensive experience in synthetic chemistry, Dr. Peng joined BioDuro in 2015, where he focused on medicinal chemistry, particularly with a strong emphasis on the chemistry synthesis of PROTACs for drug discovery.
Partner for this event
BioDuro
BioDuro, an Advent portfolio company, is a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, BioDuro employs more than 2,000 scientists with deep expertise in small- and large-molecule discovery, development, and manufacturing. We provide fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics (DMPK), along with comprehensive IND-enabling capabilities, including both drug substance and drug product development.
Related webinars
More from BioDuro.
Accelerating Clinical Entry for Poorly Soluble Molecules: A Proven and Structured Roadmap
Clinical Trial Application Success: CMC and Regulatory Insights from the US to Europe
Fueling Target Protein Degradation Drug Discovery: In Vitro Evaluation and Synthesis Strategies
Exploring Peptide In-Vitro ADME Properties: From Natural Peptides to Synthetic Analogues